$WST News

The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call

3 Reasons to Avoid WST and 1 Stock to Buy Instead

Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $425

West Pharmaceutical (WST) Signs Decade Long Daikyo Distribution Deal Beyond Japan

WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook

West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

West Pharmaceutical Services Q2 Earnings Call Highlights

West Pharmaceutical Services, Inc. 2026 Q2 - Results - Earnings Call Presentation

West Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Highlights: Strong Organic Growth ...

West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars

West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call Transcript

West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum

West Pharmaceutical Services Q2 Adjusted Earnings, Net Sales Rise; 2026 Outlook Boosted

West Reports Second-Quarter 2026 Results

Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call

West Pharmaceutical Servs Raises FY2026 Adj EPS Guidance from $8.40-$8.75 to $8.85-$9.05 vs $8.61 Est; Raises FY2026 Sales Guidance from $3.295B-$3.350B to $3.345B-$3.380B vs $3.332B Est

West Pharmaceutical Servs Raises FY2026 GAAP EPS Guidance from $8.15-$8.50 to $8.85-$9.05 vs $8.41 Est

West Pharmaceutical Servs Sees Q3 Adj EPS $2.14-$2.24 vs $2.12 Est; Sees Sales $820.000M-$835.000M vs $815.707M Est

West Pharmaceutical Servs Q2 Adj. EPS $2.37 Beats $2.08 Estimate, Sales $872.300M Beat $838.586M Estimate